As ESMO 2023 unfolds, leading pharmaceutical companies like Revolution Medicines, Daiichi Sankyo, Bristol Myers Squibb, AstraZeneca, Merus, Merck, and others eagerly anticipate the unveiling of their cutting-edge NSCLC research in oral and poster presentations. Notably, Revolution Medicines' RMC-6236 offers a sneak peek into the Phase I results.

KRAS NSCLC Highlights

• Abstract Number – #652O
• Abstract Type – Proffered Paper Session
• Indication – PDAC and NSCLC
• Target –  KRAS mutation
• Technology –  Tri-complex Technology

 

RMC-6236, Revolution Medicines' RAS^MULTI (ON) inhibitor, is designed as a first-in-class, potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants including cancer drivers at all three of the major mutation hotspot positions, G12, G13, and Q61. The drug inhibits all three major RAS isoforms, suppressing the mutant cancer driver and cooperating wild-type RAS proteins.

A monotherapy dose-escalation study of RMC-6236 is ongoing and, based on early observations from this study, it is believed that RMC-6236 is orally bioavailable and has achieved dose-dependent exposures in patients that are consistent with the preclinical projections. Revolution Medicines reported early data from this study in February 2023, in which it observed evidence of clinical activity at dose levels that were generally well tolerated.

The company currently expects to present an update on the clinical antitumor activity of RMC-6236 in patients with non-small cell lung cancer or pancreatic cancer in October 2023 and to present supporting clinical data in October 2023 as well. Planning is underway for one or more single-agent pivotal clinical trials for RMC-6236, potentially to begin in 2024.

The company is expected to discuss more detailed results in this upcoming ESMO 2023 session.

Note: The therapeutics segment is experiencing significant NSCLC clinical trial activity, which is further expected to drive Non-Small Cell Lung Caner market growth in the coming years.